Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Litzow

Showing results (231-240 of 457) with videos related to

Pageof 46
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2014
Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow TransplantationHien K Duong, Bipin N Savani, Ed Copelan, et al.
Leukemia & Lymphoma|August 20, 2005
The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphomaYinlee Yoong, Luis F Porrata, David J Inwards, et al.
Leukemia & Lymphoma|October 3, 2018
Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patientsKevin C Miller, Aref Al-Kali, Mithun V Shah, et al.
Blood Cancer Journal|June 1, 2022
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myelomaRicardo D Parrondo, Zaid Abdel Rahman, Michael G Heckman, et al.
Transplantation and Cellular Therapy|April 8, 2021
Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALLZaid H Abdel Rahman, Michael G Heckman, Kevin Miller, et al.
Blood Cancer Journal|April 9, 2023
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndromeAref Al-Kali, Ahmad Nanaa, David Viswanatha, et al.
Haematologica|May 18, 2023
Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasmsTalha Badar, Ahmad Nanaa, James M Foran, et al.
Blood|August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Transplantation and Cellular Therapy|May 18, 2025
Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell TransplantAnmol Baranwal, Christopher Graham, Khalil Hassan, et al.
Hematology (Amsterdam, Netherlands)|April 12, 2022
High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphomaJosé A Fernández-Gutiérrez, Oscar A Reyes-Cisneros, Mark R Litzow, et al.
Pageof 46

Showing results (231-240 of 457) with videos related to

Sort By:
Pageof 46
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2014
Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow TransplantationHien K Duong, Bipin N Savani, Ed Copelan, et al.
Leukemia & Lymphoma|August 20, 2005
The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphomaYinlee Yoong, Luis F Porrata, David J Inwards, et al.
Leukemia & Lymphoma|October 3, 2018
Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patientsKevin C Miller, Aref Al-Kali, Mithun V Shah, et al.
Blood Cancer Journal|June 1, 2022
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myelomaRicardo D Parrondo, Zaid Abdel Rahman, Michael G Heckman, et al.
Transplantation and Cellular Therapy|April 8, 2021
Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALLZaid H Abdel Rahman, Michael G Heckman, Kevin Miller, et al.
Blood Cancer Journal|April 9, 2023
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndromeAref Al-Kali, Ahmad Nanaa, David Viswanatha, et al.
Haematologica|May 18, 2023
Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasmsTalha Badar, Ahmad Nanaa, James M Foran, et al.
Blood|August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Transplantation and Cellular Therapy|May 18, 2025
Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell TransplantAnmol Baranwal, Christopher Graham, Khalil Hassan, et al.
Hematology (Amsterdam, Netherlands)|April 12, 2022
High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphomaJosé A Fernández-Gutiérrez, Oscar A Reyes-Cisneros, Mark R Litzow, et al.
Pageof 46